These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3633 related articles for article (PubMed ID: 7478520)

  • 1. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
    Wick ST; Dubay MM; Imanil I; Brizuela L
    Oncogene; 1995 Nov; 11(10):2013-9. PubMed ID: 7478520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
    Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
    Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
    Ceha HM; Nasser I; Medema RH; Slebos RJ
    Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
    Reymond A; Brent R
    Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations associated with familial melanoma impair p16INK4 function.
    Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
    Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y; Becker D
    Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of p16INK4a and its interaction with CDK4.
    Yang R; Serrano M; Slater J; Leung E; Koeffler HP
    Biochem Biophys Res Commun; 1996 Jan; 218(1):254-9. PubMed ID: 8573142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
    Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
    Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
    Becker TM; Rizos H; Kefford RF; Mann GJ
    Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.
    Koh J; Enders GH; Dynlacht BD; Harlow E
    Nature; 1995 Jun; 375(6531):506-10. PubMed ID: 7777061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
    Zariwala M; Liu E; Xiong Y
    Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
    Liu L; Goldstein AM; Tucker MA; Brill H; Gruis NA; Hogg D; Lassam NJ
    Genes Chromosomes Cancer; 1997 May; 19(1):52-4. PubMed ID: 9135995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
    Bahuau M; Vidaud D; Jenkins RB; Bièche I; Kimmel DW; Assouline B; Smith JS; Alderete B; Cayuela JM; Harpey JP; Caille B; Vidaud M
    Cancer Res; 1998 Jun; 58(11):2298-303. PubMed ID: 9622062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
    Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
    Liu L; Lassam NJ; Slingerland JM; Bailey D; Cole D; Jenkins R; Hogg D
    Oncogene; 1995 Jul; 11(2):405-12. PubMed ID: 7624155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
    Newton Bishop JA; Harland M; Bennett DC; Bataille V; Goldstein AM; Tucker MA; Ponder BA; Cuzick J; Selby P; Bishop DT
    Br J Cancer; 1999 Apr; 80(1-2):295-300. PubMed ID: 10390011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 182.